Related Experiment Video
Updated: May 5, 2026
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Mutational Signatures in Colorectal Cancer: Translational Insights, Clinical Applications, and Limitations
1IFOM ETS-The AIRC Institute of Molecular Oncology, 20139 Milano, Italy.
Abstract:
A multitude of exogenous and endogenous processes have the potential to result in DNA damage. While the repair mechanisms are typically capable of correcting this damage, errors in the repair process can result in mutations. The findings of research conducted in 2012 indicate that mutations do not occur randomly but rather follow specific patterns that can be attributed to known or inferred mutational processes. The process of mutational signature analysis allows for the inference of the predominant mutational process for a given cancer sample, with significant potential for clinical applications. A deeper comprehension of these mutational signatures in CRC could facilitate enhanced prevention strategies, facilitate the comprehension of genotoxic drug activity, predict responses to personalized treatments, and, in the future, inform the development of targeted therapies in the context of precision oncology. The efforts of numerous researchers have led to the identification of several mutational signatures, which can be categorized into different mutational signature references. In CRC, distinct mutational signatures are identified as correlating with mismatch repair deficiency, polymerase mutations, and chemotherapy treatment. In this context, a mutational signature analysis offers considerable potential for enhancing minimal residual disease (MRD) tests in stage II (high-risk) and stage III CRC post-surgery, stratifying CRC based on the impacts of genetic and epigenetic alterations for precision oncology, identifying potential therapeutic vulnerabilities, and evaluating drug efficacy and guiding therapy, as illustrated in a proof-of-concept clinical trial.
Insights
Mutational signature analysis reveals specific DNA damage patterns in colorectal cancer (CRC). Understanding these signatures aids in personalized treatments and developing targeted therapies for better patient outcomes.
Area of Science:
- Genomics
- Cancer Biology
- Bioinformatics
Background:
- DNA damage from various sources is common, and repair errors can lead to mutations.
- Mutations are not random; they follow specific patterns linked to mutational processes.
- Mutational signature analysis infers the primary mutational process in cancer samples.
Purpose of the Study:
- To explore the clinical applications of mutational signature analysis in colorectal cancer (CRC).
- To understand how mutational signatures can improve CRC prevention, treatment response prediction, and targeted therapy development.
- To investigate the potential of mutational signatures in enhancing minimal residual disease (MRD) detection and treatment stratification in CRC.
Main Methods:
- Analysis of mutational signatures in CRC samples.
- Categorization of identified mutational signatures into reference profiles.
- Correlation of distinct mutational signatures with specific factors like mismatch repair deficiency, polymerase mutations, and chemotherapy.
Main Results:
- Mutations exhibit non-random patterns attributable to specific mutational processes.
- Distinct mutational signatures in CRC are associated with mismatch repair deficiency, polymerase mutations, and chemotherapy.
- Mutational signature analysis shows potential for enhancing MRD tests and stratifying CRC for precision oncology.
Conclusions:
- Mutational signature analysis offers significant potential for clinical applications in CRC.
- Deeper understanding of CRC mutational signatures can guide prevention, drug activity assessment, and personalized treatment strategies.
- This analysis can aid in identifying therapeutic vulnerabilities, evaluating drug efficacy, and guiding therapy in precision oncology.
Related Concept Videos
02:18Cancer
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...